Proglumetacin

Proglumetacin is an orally active and potent cyclo-oxygenase inhibitor. Proglumetacin can inhibits SARS-CoV Mpro (main protease of the SARS-CoV-2), with an AC50 of 8.9 μM (activity concentration at half maximal activity) . Proglumetacin has anti-inflammatory activity, can be used for inflammation (such as Rheumatoid arthritis, and Allergic air pouch inflammation) research[1][2][3].

Product Specifications

CAS Number

[57132-53-3]

UNSPSC

12352005

Target

COX; SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection; Immunology/Inflammation

Applications

COVID-19-anti-virus

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/proglumetacin.html

Solubility

10 mM in DMSO

Smiles

O=C(CC1=C(C)N(C(C2=CC=C(C=C2)Cl)=O)C3=C1C=C(C=C3)OC)OCCN4CCN(CCCOC(CCC(C(N(CCC)CCC)=O)NC(C5=CC=CC=C5)=O)=O)CC4

Molecular Formula

C46H58ClN5O8

Molecular Weight

844.43

References & Citations

[1]NaohikoOno, et al. Effects of proglumetacin maleate and its major metabolites on allergic air pouch inflammation in rats. Eur J Pharmacol. 1987;142 (2) :245-251.|[2]Ono N, et al. Pharmacological studies on proglumetacin maleate, a new non-steroidal anti-inflammatory drug (4) . Mode of action on anti-inflammatory activity. Japanese Journal of Pharmacology, 1986, 42 (3) :431-9.|[3]Alves VM, et al. QSAR Modeling of SARS-CoV Mpro Inhibitors Identifies Sufugolix, Cenicriviroc, Proglumetacin, and other Drugs as Candidates for Repurposing against SARS-CoV-2. Mol Inform. 2021 Jan;40 (1) :e2000113.|[4]Bozsoky S, Zahumenszky Z. A 3-month, double-blind study of proglumetacin and naproxen in the treatment of rheumatoid arthritis. Curr Med Res Opin. 1982;8 (2) :89-96.